# Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy

> **NCT00312988** · PHASE3 · COMPLETED · sponsor: **North Eastern German Society of Gynaecological Oncology** · enrollment: 450 (—)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Hycamtin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00312988
- **Lead sponsor:** North Eastern German Society of Gynaecological Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** —
- **Final completion:** 2009-12
- **Target enrollment:** 450 (—)
- **Last updated:** 2006-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00312988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00312988, "Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00312988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*